Volume 56, Issue 5, Pages 753-760 (November 2009) Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort  Andrew J. Vickers, Tineke Wolters, Caroline J. Savage, Angel M. Cronin, M. Frank O’Brien, Kim Pettersson, Monique J. Roobol, Gunnar Aus, Peter T. Scardino, Jonas Hugosson, Fritz H. Schröder, Hans Lilja  European Urology  Volume 56, Issue 5, Pages 753-760 (November 2009) DOI: 10.1016/j.eururo.2009.07.047 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Flow of participants through the study. European Urology 2009 56, 753-760DOI: (10.1016/j.eururo.2009.07.047) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Predicted probability of a positive biopsy with increasing prostate-specific antigen (PSA) velocity, controlling for PSA. Probabilities are for a subject with a PSA level of 4.3 ng/ml, which was the mean PSA for the cohort. Black line: modeled with nonlinear terms; gray line: modeled with only a linear term; dashed lines: 95% confidence intervals. European Urology 2009 56, 753-760DOI: (10.1016/j.eururo.2009.07.047) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Decision curve analysis. The curves show the clinical benefit for basing biopsy decisions on the models with total prostate-specific antigen (PSA) plus age (dotted line), total PSA plus age plus free-to-total PSA ratio (%fPSA; dashed line), and total PSA plus age plus %fPSA plus PSA velocity (thin solid line); biopsy all men (thick grey line); and biopsy no man (thick black line). European Urology 2009 56, 753-760DOI: (10.1016/j.eururo.2009.07.047) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 4 Decision curve analysis for men with prostate-specific antigen (PSA) velocity <0.75 ng/ml per year. Total PSA plus age (dotted line), total PSA plus age plus free-to-total PSA ratio (%fPSA; dashed line), total PSA plus age plus %fPSA plus PSA velocity (thin solid line), biopsy all men (thick grey line), biopsy no man (thick black line). European Urology 2009 56, 753-760DOI: (10.1016/j.eururo.2009.07.047) Copyright © 2009 European Association of Urology Terms and Conditions